Loading...
Market
Will subcutaneous Nivolumab reach $1 billion in sales by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Bristol Myers Squibb's financial reports or reputable financial news sources
Story
FDA Approves Subcutaneous Nivolumab by Bristol Myers Squibb for Advanced or Metastatic Solid Tumors
Dec 27, 2024, 04:10 PM
The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of Nivolumab, also known as Opdivo, for use in patients with advanced or metastatic solid tumors. This approval, announced on December 27, 2024, allows for an injectable version of the drug, which is manufactured by Bristol Myers Squibb. The approval is expected to enhance treatment options for patients suffering from various types of cancer, including lung and gastrointestinal cancers, as well as breast cancer, where recent studies have indicated the drug's efficacy in combination with other therapies. The FDA's decision follows a series of discussions and presentations at recent oncology conferences, highlighting the importance of personalized cancer care and the role of biomarkers in treatment decisions.
View original story
Similar markets
No significant increase • 25%
Increase by less than 10% • 25%
Increase between 10% and 20% • 25%
Increase by more than 20% • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
AstraZeneca • 25%
Less than $50 million • 25%
More than $200 million • 25%
$100 million to $200 million • 25%
$50 million to $100 million • 25%
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
Roche • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Approved in UK and EU • 25%
Not approved in any major market • 25%
Approved in UK only • 25%
Approved in UK, EU, and USA • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
